多発血管炎性肉芽腫症治療の世界市場レポート 2025年

多発血管炎性肉芽腫症治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.9％で34億7,000万米ドルに成長します。予測期間中の成長は、自己免疫疾患の有病率の上昇、肉芽腫症の発生率の増加、多発血管炎の発生率の増加、免疫疾患の急増に起因しています。予測期間における主な動向には、医薬品開発の進展、ヘルスケアの進歩、診断技術の改善、治療選択肢の革新、生物製剤およびバイオシミラーの開発などが含まれます。

自己免疫疾患の有病率の増加は、多発血管炎性肉芽腫症治療市場の拡大を促進すると予想されます。自己免疫疾患は、身体の免疫システムが誤って健康な細胞や組織を標的とし、様々な臓器に炎症や損傷を引き起こすことで発生します。この有病率の増加は、感染症、化学物質、汚染物質、ライフスタイルの変化などの環境誘因と関連しています。多発血管炎性肉芽腫症治療は、コルチコステロイドやシクロホスファミドなどの免疫抑制療法を用いることで、炎症を抑え、臓器の損傷を防ぐ自己免疫疾患の管理に重要な役割を果たしています。早期介入と個別化治療は、同様のメカニズムを持つ他の自己免疫疾患の管理にも不可欠です。例えば、英国の政府機関である国家統計局が2023年6月に発表した報告書によると、自己免疫疾患の一つである多発性硬化症（MS）に罹患する世界人口は、2022年の280万人から2023年には290万人に増加します。その結果、自己免疫疾患の有病率の上昇が多発血管炎性肉芽腫症治療市場の成長を促進しています。

多発血管炎性肉芽腫症治療市場の主要企業は、経口コルチコステロイドなどの革新的な製品の開発に重点を置いており、ステロイド使用による長期的な副作用を軽減しながら、疾患管理を改善する、より効果的な治療オプションを提供しています。経口コルチコステロイドは炎症を緩和し、免疫系を抑制する働きがあり、アレルギー、自己免疫疾患、炎症性疾患に広く使用されています。例えば、2024年10月、英国の製薬会社AstraZeneca plcは、再発性または難治性の多発血管炎を伴う好酸球性肉芽腫症（EGPA）の成人患者に対する追加治療薬として、欧州連合（EU）においてファセンラ（ベバシズマブ）が承認されたと発表しました。今回の承認は、MANDARA第III相試験で良好な結果が得られたことを受けたもので、EGPA患者においてファセンラが寛解を達成し、経口コルチコステロイド薬への依存を減少させる有効性が実証されました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界多発血管炎性肉芽腫症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の多発血管炎性肉芽腫症治療市場：成長率分析
• 世界の多発血管炎性肉芽腫症治療市場の実績：規模と成長, 2019-2024
• 世界の多発血管炎性肉芽腫症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界多発血管炎性肉芽腫症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の多発血管炎性肉芽腫症治療市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ステロイド
• 免疫抑制剤
• その他の薬物の種類
• 世界の多発血管炎性肉芽腫症治療市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫抑制剤
• コルチコステロイド
• 生物学的製剤
• 疾患修飾性抗リウマチ薬（DMARD）
• その他の治療の種類
• 世界の多発血管炎性肉芽腫症治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内
• 世界の多発血管炎性肉芽腫症治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の多発血管炎性肉芽腫症治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の多発血管炎性肉芽腫症治療市場ステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレドニゾン
• メチルプレドニゾロン
• デキサメタゾン
• ヒドロコルチゾン
• 世界の多発血管炎性肉芽腫症治療市場免疫抑制剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• シクロホスファミド
• メトトレキサート
• アザチオプリン
• ミコフェノール酸モフェチル
• リツキシマブ
• 世界の多発血管炎性肉芽腫症治療市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血漿交換療法
• 静脈内免疫グロブリン（IVIG）
• 生物学的製剤
• 非ステロイド性抗炎症薬（NSAID）

第7章 地域別・国別分析

• 世界の多発血管炎性肉芽腫症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の多発血管炎性肉芽腫症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 多発血管炎性肉芽腫症治療市場：競合情勢
• 多発血管炎性肉芽腫症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Vertex Pharmaceuticals Incorporated
• Genentech Inc.
• Incyte Corporation
• Alnylam Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• ChemoCentryx Inc.
• Medac Pharma Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 多発血管炎性肉芽腫症治療市場2029：新たな機会を提供する国
• 多発血管炎性肉芽腫症治療市場2029：新たな機会を提供するセグメント
• 多発血管炎性肉芽腫症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Granulomatosis with Polyangiitis (GPA) treatment includes medications aimed at controlling inflammation, suppressing the immune system, and preventing organ damage. GPA is a rare autoimmune disease that causes inflammation in small to medium-sized blood vessels, leading to restricted blood flow and tissue damage, particularly affecting the respiratory tract and kidneys. The primary treatment approach involves immunosuppressive therapies, including corticosteroids and biologics, to reduce inflammation and protect organ function.

The key drug categories for treating granulomatosis with polyangiitis include steroids, immunosuppressants, and others. Steroids are anti-inflammatory medications that help decrease swelling and suppress immune activity. In GPA management, they are commonly used alongside other drugs to control symptoms. The treatment approaches involve immunosuppressants and corticosteroids, administered through various routes such as oral and intravenous. These medications are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are utilized by different end users, including hospitals, home care, specialty clinics, and others.

The granulomatosis with polyangiitis treatment market research report is one of a series of new reports from The Business Research Company that provides granulomatosis with polyangiitis treatment market statistics, including the granulomatosis with polyangiitis treatment industry global market size, regional shares, competitors with the granulomatosis with polyangiitis treatment market share, detailed granulomatosis with polyangiitis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the granulomatosis with polyangiitis treatment industry. This granulomatosis with polyangiitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The granulomatosis with polyangiitis treatment market size has grown strongly in recent years. It will grow from $2.36 billion in 2024 to $2.56 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth during the historic period can be attributed to the increasing demand for drugs, the rising number of clinical trials, the growing need for effective treatment, the heightened focus on personalized medicine, and higher diagnosis rates of the disorder.

The granulomatosis with polyangiitis treatment market size is expected to see strong growth in the next few years. It will grow to $3.47 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth during the forecast period can be attributed to the rising prevalence of autoimmune diseases, the increasing occurrence of granulomatosis, the growing incidences of polyangiitis, and the surge in immunological disorders. Key trends in the forecast period include advancements in drug development, progress in healthcare, improvements in diagnostic techniques, innovations in treatment options, and the development of biologics and biosimilars.

The growing prevalence of autoimmune diseases is expected to drive the expansion of the granulomatosis with polyangiitis treatment market. Autoimmune diseases arise when the body's immune system mistakenly targets healthy cells and tissues, causing inflammation and damage across various organs. This increasing prevalence is linked to environmental triggers such as infections, chemicals, pollutants, and lifestyle changes. Granulomatosis with polyangiitis treatment plays a crucial role in managing autoimmune diseases by using immunosuppressive therapies such as corticosteroids and cyclophosphamide, which help control inflammation and prevent organ damage. Early intervention and personalized treatment are essential for managing other autoimmune conditions with similar mechanisms. For example, according to a report published in June 2023 by the Office for National Statistics, a UK-based government department, the global population affected by multiple sclerosis (MS), an autoimmune disease, increased from 2.8 million in 2022 to 2.9 million in 2023. As a result, the rising prevalence of autoimmune diseases is fueling the growth of the granulomatosis with polyangiitis treatment market.

Leading companies in the granulomatosis with polyangiitis treatment market are emphasizing the development of innovative products, such as oral corticosteroids, to provide more effective treatment options that improve disease management while reducing the long-term side effects of steroid use. Oral corticosteroids help alleviate inflammation and suppress the immune system and are widely used for allergies, autoimmune diseases, and inflammatory disorders. For instance, in October 2024, AstraZeneca plc, a UK-based pharmaceutical company, announced the approval of Fasenra (bevacizumab) in the European Union as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). This approval followed positive findings from the MANDARA Phase III trial, which demonstrated Fasenra's effectiveness in achieving remission and decreasing dependency on oral corticosteroids in EGPA patients.

In October 2022, Amgen Inc., a US-based biotechnology company, acquired ChemoCentryx Inc. for $3.7 billion. This acquisition aims to bolster Amgen's inflammation and nephrology portfolio by broadening the market reach of Tavneos (avacopan) and enhancing its presence in autoimmune and rare disease treatments. ChemoCentryx Inc. is a US-based company specializing in treatments for granulomatosis with polyangiitis and other inflammatory diseases.

Major players in the granulomatosis with polyangiitis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech Inc., Incyte Corporation, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., ChemoCentryx Inc., Medac Pharma Inc., InflaRx GmbH.

North America was the largest region in the granulomatosis with polyangiitis treatment market in 2024. The regions covered in granulomatosis with polyangiitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the granulomatosis with polyangiitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The granulomatosis with polyangiitis treatment market includes sales of symptomatic treatment, monoclonal antibodies, and plasmapheresis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Granulomatosis With Polyangiitis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on granulomatosis with polyangiitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for granulomatosis with polyangiitis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The granulomatosis with polyangiitis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Steroids; Immunosuppressant; Other Drug Types
• 2) By Treatment Type: Immunosuppressants; Corticosteroids
• 3) By Route Of Administration: Oral; Intravenous
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Steroids: Prednisone; Methylprednisolone; Dexamethasone; Hydrocortisone
• 2) By Immunosuppressants: Cyclophosphamide; Methotrexate; Azathioprine; Mycophenolate mofetil; Rituximab
• 3) By Other Drug Types: Plasma Exchange Therapy; Intravenous Immunoglobulin (IVIG); Biologic Agents; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Sanofi S.A.; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Granulomatosis With Polyangiitis Treatment Market Characteristics

3. Granulomatosis With Polyangiitis Treatment Market Trends And Strategies

4. Granulomatosis With Polyangiitis Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Granulomatosis With Polyangiitis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Granulomatosis With Polyangiitis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Granulomatosis With Polyangiitis Treatment Market Growth Rate Analysis
• 5.4. Global Granulomatosis With Polyangiitis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Granulomatosis With Polyangiitis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Granulomatosis With Polyangiitis Treatment Total Addressable Market (TAM)

6. Granulomatosis With Polyangiitis Treatment Market Segmentation

• 6.1. Global Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Steroids
• Immunosuppressant
• Other Drug Types
• 6.2. Global Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressants
• Corticosteroids
• Biologics
• Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
• Other Treatment Types
• 6.3. Global Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• 6.4. Global Granulomatosis With Polyangiitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Granulomatosis With Polyangiitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Granulomatosis With Polyangiitis Treatment Market, Sub-Segmentation Of Steroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Methylprednisolone
• Dexamethasone
• Hydrocortisone
• 6.7. Global Granulomatosis With Polyangiitis Treatment Market, Sub-Segmentation Of Immunosuppressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cyclophosphamide
• Methotrexate
• Azathioprine
• Mycophenolate mofetil
• Rituximab
• 6.8. Global Granulomatosis With Polyangiitis Treatment Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plasma Exchange Therapy
• Intravenous Immunoglobulin (IVIG)
• Biologic Agents
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

7. Granulomatosis With Polyangiitis Treatment Market Regional And Country Analysis

• 7.1. Global Granulomatosis With Polyangiitis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Granulomatosis With Polyangiitis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Granulomatosis With Polyangiitis Treatment Market

• 8.1. Asia-Pacific Granulomatosis With Polyangiitis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Granulomatosis With Polyangiitis Treatment Market

• 9.1. China Granulomatosis With Polyangiitis Treatment Market Overview
• 9.2. China Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Granulomatosis With Polyangiitis Treatment Market

• 10.1. India Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Granulomatosis With Polyangiitis Treatment Market

• 11.1. Japan Granulomatosis With Polyangiitis Treatment Market Overview
• 11.2. Japan Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Granulomatosis With Polyangiitis Treatment Market

• 12.1. Australia Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Granulomatosis With Polyangiitis Treatment Market

• 13.1. Indonesia Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Granulomatosis With Polyangiitis Treatment Market

• 14.1. South Korea Granulomatosis With Polyangiitis Treatment Market Overview
• 14.2. South Korea Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Granulomatosis With Polyangiitis Treatment Market

• 15.1. Western Europe Granulomatosis With Polyangiitis Treatment Market Overview
• 15.2. Western Europe Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Granulomatosis With Polyangiitis Treatment Market

• 16.1. UK Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Granulomatosis With Polyangiitis Treatment Market

• 17.1. Germany Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Granulomatosis With Polyangiitis Treatment Market

• 18.1. France Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Granulomatosis With Polyangiitis Treatment Market

• 19.1. Italy Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Granulomatosis With Polyangiitis Treatment Market

• 20.1. Spain Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Granulomatosis With Polyangiitis Treatment Market

• 21.1. Eastern Europe Granulomatosis With Polyangiitis Treatment Market Overview
• 21.2. Eastern Europe Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Granulomatosis With Polyangiitis Treatment Market

• 22.1. Russia Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Granulomatosis With Polyangiitis Treatment Market

• 23.1. North America Granulomatosis With Polyangiitis Treatment Market Overview
• 23.2. North America Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Granulomatosis With Polyangiitis Treatment Market

• 24.1. USA Granulomatosis With Polyangiitis Treatment Market Overview
• 24.2. USA Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Granulomatosis With Polyangiitis Treatment Market

• 25.1. Canada Granulomatosis With Polyangiitis Treatment Market Overview
• 25.2. Canada Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Granulomatosis With Polyangiitis Treatment Market

• 26.1. South America Granulomatosis With Polyangiitis Treatment Market Overview
• 26.2. South America Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Granulomatosis With Polyangiitis Treatment Market

• 27.1. Brazil Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Granulomatosis With Polyangiitis Treatment Market

• 28.1. Middle East Granulomatosis With Polyangiitis Treatment Market Overview
• 28.2. Middle East Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Granulomatosis With Polyangiitis Treatment Market

• 29.1. Africa Granulomatosis With Polyangiitis Treatment Market Overview
• 29.2. Africa Granulomatosis With Polyangiitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Granulomatosis With Polyangiitis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Granulomatosis With Polyangiitis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Granulomatosis With Polyangiitis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Granulomatosis With Polyangiitis Treatment Market Competitive Landscape
• 30.2. Granulomatosis With Polyangiitis Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Granulomatosis With Polyangiitis Treatment Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Eli Lilly and Company
• 31.3. Gilead Sciences Inc.
• 31.4. Amgen Inc.
• 31.5. Teva Pharmaceutical Industries Ltd.
• 31.6. Otsuka Pharmaceutical Co. Ltd.
• 31.7. Regeneron Pharmaceuticals Inc.
• 31.8. Astellas Pharma Inc.
• 31.9. Vertex Pharmaceuticals Incorporated
• 31.10. Genentech Inc.
• 31.11. Incyte Corporation
• 31.12. Alnylam Pharmaceuticals Inc.
• 31.13. Ionis Pharmaceuticals Inc.
• 31.14. ChemoCentryx Inc.
• 31.15. Medac Pharma Inc.

32. Global Granulomatosis With Polyangiitis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Granulomatosis With Polyangiitis Treatment Market

34. Recent Developments In The Granulomatosis With Polyangiitis Treatment Market

35. Granulomatosis With Polyangiitis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Granulomatosis With Polyangiitis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Granulomatosis With Polyangiitis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Granulomatosis With Polyangiitis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer